Director/PDMR Shareholding

Thruvision

29/09/2025 11:26

RNS Number : 2230B

Thruvision Group PLC

29 September 2025

 

29 September 2025

 

Thruvision Group plc

 

("Thruvision" or the "Company")

 

Director Share Dealing

 

Thruvision (AIM: THRU, "Thruvision" or the "Group"), the leading international provider of walk- through security technology, announces that on 26 September 2025 Mark Nurse, the husband and accordingly a person closely associated ("PCA") with Katrina Nurse, sold 10,000 ordinary shares in the Company at a price of 1.23 pence.

 

Following this transaction, the beneficial shareholding in the Company of Katrina Nurse and her PCAs is 258,000 ordinary shares, representing 0.06% of the Company's total issued share capital and total voting rights.

 

The notification below, made in accordance with the requirements of the Market Abuse Regulation, provides further detail:

 

1.
Details of the person discharging managerial responsibilities/person closely associated
(a)
Name
Mark Nurse, husband of Katrina Nurse
2.
Reason for the notification
(a)
Position/status
Person closely associated with Katrina Nurse, a Non-Executive Director
(b)
Initial notification/ Amendment
Initial notification
3.
Details of the issuer
(a)
Name
Thruvision Group plc
(b)
LEI
213800IZG9GM6G2TZE04
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
(a)
Description of the Financial Instrument
Ordinary shares of £0.01 each
(b)
Identification code of the Financial Instrument
GB00B627R876
(c)
Nature of the transaction
Sale of shares
(d)
Price(s) and volume(s)
Price(s)
Volume(s)
1.23 pence
10,000
(e)
Aggregated information
- Aggregated volume
- Price
N/A
(f)
Date of the transaction
26 September 2025
(g)
Place of the transaction
London Stock Exchange

 

For further information please contact:

 

Thruvision Group plc
Tom Black, Executive Chairman
Victoria Balchin, Chief Executive Officer and Chief Financial Officer
+44 (0)1235 425 400
Allenby (Nominated Adviser & Broker)
James Reeve / Piers Shimwell (Corporate Finance)
Jos Pinnington / Amrit Nahal (Sales)
+44 (0)20 3328 5656


 

About Thruvision (www.thruvision.com)

Thruvision is a leading developer, manufacturer and supplier of advanced AI-based walk- through security technology internationally. Its technology is deployed in more than 30 countries around the world by government and commercial organisations in a wide range of security situations, where large numbers of people need to be screened quickly, safely and efficiently. Thruvision's patented technology is uniquely capable of detecting concealed objects in real time using advanced AI-based detection algorithms. The Group's offices are near Oxford and Washington DC.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
DSHBGGDCUDDDGUC